Immix Biopharma (IMMX) Other Non Operating Income (2021)

Immix Biopharma (IMMX) posted Other Non Operating Income of $728768.0 for Q4 2021, up 909.74% sequentially from -$90000.0 in Q2 2021.

Immix Biopharma (IMMX) Other Non Operating Income (2021) Analysis & Trends

Immix Biopharma has reported Other Non Operating Income for 1 years, with the latest figure at $728768.0 in Q4 2021.

Quarterly Other Non Operating Income changed N/A year-over-year to $728768.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was -$186232.0 (changed N/A YoY) and the FY2025 annual result came in at $2.1 million, up 4395.21% from the prior year.
Other Non Operating Income improved to $728768.0 in Q4 2021 per IMMX's latest filing, from -$90000.0 in the prior quarter.
Over five years, Other Non Operating Income peaked at $728768.0 in Q4 2021 and troughed at -$825000.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Immix Biopharma	784.75 Mn	784.75 Mn	-

Download Data